REVITALIZE RUG AND ROOM DEODORIZER

المعلومات الرئيسية

  • اسم تجاري:
  • REVITALIZE RUG AND ROOM DEODORIZER
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • REVITALIZE RUG AND ROOM DEODORIZER
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 975573-03
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج: الجرعة، والتفاعلات والآثار الجانبية

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

1 / 6

REVITALIZE RUG AND ROOM DEODORIZER

00971 4 8014444

00971 48146800 00971 4 8014000

0020 2 25 37 1195

00212 22 58 25 30 - 35

00971 4 8014444 :

00971 48146800 00971 4 8014000

0020 2 25 37 1195 :

00212 22 58 25 30 - 35 :

14.08.2017

GHS

:

:

:

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

2 / 6

(%)

starch

9005-25-8

5 - 10

aluminium oxide

1344-28-1

1 - 5

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

3 / 6

-5 °C

50 °C

starch

9005-25-8

TWA OEL-RL

5 mg/m3

TWA OEL-RL

10 mg/m3

starch

9005-25-8

10 mg/m3

BH OEL

starch

9005-25-8

10 mg/m3

ARE OEL

aluminium oxide

1344-28-1

TWA OEL-RL

5 mg/m3

TWA OEL-RL

10 mg/m3

aluminium oxide

1344-28-1

10 mg/m3

BH OEL

aluminium oxide

1344-28-1

1 mg/m3

ARE OEL

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

4 / 6

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

5 / 6

> 5,000 mg/kg :

REVITALIZE RUG AND ROOM DEODORIZER

975573-03

6 / 6

(ADR/ADN/RID)

)

(

)

IMDG/

(

14.08.2017

Regulatory Affairs

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

17-12-2018

Vijf jaar NIX brengt normverandering roken en drinken op gang

Vijf jaar NIX brengt normverandering roken en drinken op gang

Op 1 januari is het precies vijf jaar geleden dat de leeftijdsgrens voor roken en drinken werd verhoogd naar 18 jaar. In deze periode is er veel veranderd, blijkt uit een recente peiling in opdracht van het ministerie van VWS. Zo vindt ongeveer driekwart van de ouders en tieners het ‘normaal’ dat je pas mag roken en drinken vanaf 18 jaar. 78,2% van de ouders vindt dit tegenover 75,4% van de jongeren. De afgelopen jaren is het gebruik van alcohol onder tieners teruggelopen. Sinds 2011 gaat het in de total...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

13-12-2018

FDA Works to Keep Injectable Opioids Available to Treat Animals’ Surgical and Trauma Pain During Ongoing Supply Shortage

FDA Works to Keep Injectable Opioids Available to Treat Animals’ Surgical and Trauma Pain During Ongoing Supply Shortage

In its continuing mission to protect animal health, the U.S. Food and Drug Administration announced that it has worked with Pfizer Inc to alleviate a shortage of injectable opioids available to treat pain in animals, by facilitating the availability of a limited amount of product labeled for humans.

FDA - U.S. Food and Drug Administration

13-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D., on efforts to modernize generic drug labels while maintaining the efficiency of generic development

Statement from FDA Commissioner Scott Gottlieb, M.D. and Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D., on efforts to modernize generic drug labels while maintaining the efficiency of generic development

FDA announces withdrawal of the proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products

FDA - U.S. Food and Drug Administration

12-12-2018

December 4, 2018: Des Moines Residents Sentenced for Felony Federal Food, Drug, and Cosmetic Act Offense

December 4, 2018: Des Moines Residents Sentenced for Felony Federal Food, Drug, and Cosmetic Act Offense

December 4, 2018: Des Moines Residents Sentenced for Felony Federal Food, Drug, and Cosmetic Act Offense

FDA - U.S. Food and Drug Administration

12-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s efforts to improve drug quality through vigilant oversight of data integrity and good manufacturing practice

FDA releases guidance with recommendations for drug manufacturers regarding good manufacturing practices and data integrity

FDA - U.S. Food and Drug Administration

11-12-2018

National Drug Code Directory

National Drug Code Directory

National Drug Code Directory

FDA - U.S. Food and Drug Administration

10-12-2018

Public Notification: On Demand contains hidden drug ingredient

Public Notification: On Demand contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use On Demand, a product promoted and sold for sexual enhancement on various websites, including www.goodlifeondemand.com, and possibly in some retail stores.

FDA - U.S. Food and Drug Administration

10-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new efforts to assure the quality of compounded drugs

Statement from FDA Commissioner Scott Gottlieb, M.D. and Deputy Commissioner Anna Abram on new efforts to assure the quality of compounded drugs

FDA releases guidance with recommendations for protecting patients from the risk of contaminated or substandard compounded products produced by outsourcing facilities.

FDA - U.S. Food and Drug Administration

6-12-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics

Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s new strategic framework to advance use of real-world evidence to support development of drugs and biologics

FDA releases new strategic framework to advance use of real-world evidence to support development of drugs and biologics

FDA - U.S. Food and Drug Administration

6-12-2018

FDA Working with Stakeholders to Maintain Effectiveness of Livestock and Horse Dewormers

FDA Working with Stakeholders to Maintain Effectiveness of Livestock and Horse Dewormers

The U.S. Food and Drug Administration announced today that it has requested that animal drug companies voluntarily revise the labels of animal drugs intended to treat certain internal parasites in livestock and horses to add information about antiparasitic resistance.

FDA - U.S. Food and Drug Administration

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

3-12-2018

November 29, 2018: Two Practitioners Sentenced for Drug Crimes in Connection with HOPE Clinic

November 29, 2018: Two Practitioners Sentenced for Drug Crimes in Connection with HOPE Clinic

November 29, 2018: Two Practitioners Sentenced for Drug Crimes in Connection with HOPE Clinic

FDA - U.S. Food and Drug Administration

3-12-2018

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

January 11, 2019: Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

3-12-2018

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

January 16, 2019: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

30-11-2018

Public Notification: MOB Candy contains hidden drug ingredients

Public Notification: MOB Candy contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use MOB Candy, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

FDA - U.S. Food and Drug Administration

30-11-2018

Public Notification: Willy Go Wild contains hidden drug ingredients

Public Notification: Willy Go Wild contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Willy Go Wild, a product promoted and sold for sexual enhancement on various websites and in some retail stores.

FDA - U.S. Food and Drug Administration

29-11-2018

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab).

FDA - U.S. Food and Drug Administration

27-11-2018

FDA warns consumers to avoid Rhino male enhancement products found at retailers because of undeclared and potentially dangerous drug ingredients

FDA warns consumers to avoid Rhino male enhancement products found at retailers because of undeclared and potentially dangerous drug ingredients

FDA issues a warning to consumers to beware of and avoid certain male enhancement products that may be dangerous to their health

FDA - U.S. Food and Drug Administration

26-11-2018

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

The FDA granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

FDA - U.S. Food and Drug Administration

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

23-11-2018

FDA Classifies Field Action Related to Fc 500™ And Epics® As Class 1 Recall Beckman Coulter Life Sciences Committed to Helping Customers Take Prompt, Appropriate Actions

FDA Classifies Field Action Related to Fc 500™ And Epics® As Class 1 Recall Beckman Coulter Life Sciences Committed to Helping Customers Take Prompt, Appropriate Actions

Beckman Coulter Life Sciences today announced the previously communicated global voluntary recall launched in January 2018 related to the FC 500™ Series Flow Cytometers (FC 500), COULTER® EPICS® XL™ and COULTER® EPICS® XL-MCL™ Flow Cytometer with System II Software (together referred to as the EPICS) has been classified as Class 1 by the U.S. Food and Drug Administration (FDA).

FDA - U.S. Food and Drug Administration

23-11-2018

Nationaal Preventieakkoord verbetert gezondheid van alle Nederlanders

Nationaal Preventieakkoord verbetert gezondheid van alle Nederlanders

Met het Nationaal Preventieakkoord gaan meer dan 70 partijen samen aan de slag om Nederland gezonder te maken en gezondheidsverschillen te verkleinen. Het akkoord bestaat uit een uitgebreid pakket aan afspraken en maatregelen over het terugdringen van roken, overgewicht en problematisch alcoholgebruik. Met vereende krachten willen de deelnemers onder andere bereiken dat er in 2040 een rookvrije generatie is ontstaan, dat jongeren en zwangeren geen alcohol drinken, iedereen veel bewuster is van de risico’...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

22-11-2018

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

Foreign Product Alert: Black Lion Pill, Help 100% & Pure Natural & Body Slim capsules, Herba Saraf, Horny Little Devil, Ja Dera Max capsules, Lida (Plus) capsules, Nutra Organics Green Tea Extract capsules, Papapa, Red Zone Xtreme 3000, Rhino 69 Extreme 5

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients and/or unacceptable contaminant(s).

Health Canada

22-11-2018

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

Foreign Product Alert: Black Ant King tablets, Gold Viagra 9800mg capsules, LIPRO Dietary capsules, Stree Overlord Strong tablets (pills), Vegetal Vigra capsules, ViaGro 500mg Male Enhancement capsules

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients.

Health Canada

21-11-2018

Public Notification: Pink Granada contains hidden drug ingredients

Public Notification: Pink Granada contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Pink Granada, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

21-11-2018

Public Notification: America Treasure contains hidden drug ingredient

Public Notification: America Treasure contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use America Treasure, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

The FDA approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.

FDA - U.S. Food and Drug Administration

20-11-2018

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine

FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started or while it was being taken. This MS worsening is rare but can result in permanent disability.

FDA - U.S. Food and Drug Administration

17-11-2018

Recall of Green Cedar Dairy Ackawi Cheese Bearing a Sell by Date of March 26, 2019 or Later

Recall of Green Cedar Dairy Ackawi Cheese Bearing a Sell by Date of March 26, 2019 or Later

Routine samples of the Green Cedar Ackawi cheese collected and tested by the U.S. Food and Drug Administration and the Michigan Department of Agriculture and Rural Development tested positive for the presence of Listeria monocytogenes.

FDA - U.S. Food and Drug Administration

16-11-2018

FDA approves new drug to treat travelers’ diarrhea

FDA approves new drug to treat travelers’ diarrhea

FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement from USDA Secretary Perdue and FDA Commissioner Gottlieb on the regulation of cell-cultured food products from cell lines of livestock and poultry

Statement from USDA Secretary Perdue and FDA Commissioner Gottlieb on the regulation of cell-cultured food products from cell lines of livestock and poultry

The U.S. Department of Agriculture and U.S. Food and Drug Administration are announcing that USDA and FDA should jointly oversee the production of cell-cultured food products derived from livestock and poultry.

FDA - U.S. Food and Drug Administration

16-11-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s efforts to hold industry accountable for fulfilling critical post-marketing studies of the benefits, safety of new drugs

The FDA is committed to making sure post-market studies are transparent to the public and that industry is fulfilling their PMRs and PMCs.

FDA - U.S. Food and Drug Administration

16-11-2018

FDA Proposes Study with Intent of Eliminating Use of Dogs in Certain Types of Research

FDA Proposes Study with Intent of Eliminating Use of Dogs in Certain Types of Research

In keeping with the goals of reducing, replacing, and/or refining the use of animals in research, the U.S. Food and Drug Administration today released for public comment proposed research to validate an alternative approach for bioequivalence studies for certain animal drugs.

FDA - U.S. Food and Drug Administration

15-11-2018

Vanpak Limited recalls various Cosmetic products in pressurised containers.

Vanpak Limited recalls various Cosmetic products in pressurised containers.

The recalled products do not have mandatory hazard labelling as required by the Cosmetics Regulations under the Food and Drugs Act. Improper labelling could result in misuse of the product and lead to serious injury.

Health Canada

15-11-2018

MPS Canada Corporation recalls various Cosmetic products in pressurised containers.

MPS Canada Corporation recalls various Cosmetic products in pressurised containers.

The recalled products do not have mandatory hazard labelling as required by the Cosmetics Regulations under the Food and Drugs Act. Improper labelling could result in misuse of the product and lead to serious injury.

Health Canada

13-11-2018

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA published draft guidance for industry #243 “Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing MRLs and Withdrawal Periods.”

FDA - U.S. Food and Drug Administration

12-11-2018

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins ondertekent actieplan ambulancezorg

Minister Bruno Bruins (Medische Zorg), Ambulancezorg Nederland (AZN) en Zorgverzekeraars Nederland (ZN) presenteerden vandaag het actieplan ambulancezorg. Het actieplan bevat verbeteringen waarmee ambulancezorg efficiënter kan worden ingezet en waarmee de opleiding en inzet van personeel in de regio’s gestroomlijnd wordt. Ook is er aandacht voor het aantrekkelijker maken van de vakopleiding. Door meer flexibiliteit in de bekostiging van ambulancezorg wordt het makkelijker om maatwerk te leveren in de reg...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

9-11-2018

An increase in poisonings due to wild mushroom consumption: be vigilant!

An increase in poisonings due to wild mushroom consumption: be vigilant!

In response to an increase in the number of cases of poisonings due to wild mushroom consumption reported to the French Poison Control and Monitoring Centres (CAP-TVs), ANSES and the Directorate General for Health (DGS) are issuing a warning to wild mushroom gatherers and reminding them of the good practices to be observed.

France - Agence Nationale du Médicament Vétérinaire

9-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen and modernize agency’s oversight and reporting of inspections for sterile injectable drugs

FDA is taking steps to modernize the agency’s inspections program

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access program

The FDA is committed to the expanded access program which provides a pathway for patients to gain access to investigational drugs, biologics and medical devices for serious diseases and life-threatening conditions outside of clinical trials when no comparable or satisfactory approved alternative therapy options are available.

FDA - U.S. Food and Drug Administration

8-11-2018

Public Notification: Best Leopard Miracle of Honey contains hidden drug ingredients

Public Notification: Best Leopard Miracle of Honey contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Best Leopard Miracle of Honey, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

8-11-2018

Public Notification: Gold Max Blue contains hidden drug ingredient

Public Notification: Gold Max Blue contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Max Blue, a product promoted and sold for sexual enhancement on various websites, including www.goldmaxblue.com, and possibly in some retail stores.

FDA - U.S. Food and Drug Administration

8-11-2018

Public Notification: Leopard Secret Miracle Honey contains hidden drug ingredient

Public Notification: Leopard Secret Miracle Honey contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Leopard Secret Miracle Honey, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

FDA approves new version of OTC Primatene Mist inhaler to treat mild, intermittent asthma for people who have been diagnosed with asthma by their physician

FDA - U.S. Food and Drug Administration

8-11-2018

Theme event on big data and medicine

Theme event on big data and medicine

The U.S. Food and Drug Administration, FDA, The European Medicines Agency, EMA, and Novo Nordisk are among the speakers when The Danish Medicines Agency on 20 November 2018 puts focus on big data and medicine under the event heading “From Big Data to Real World Evidence”.

Danish Medicines Agency

7-11-2018

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be sterile, are manufactured without necessary production controls and conditions to assure sterility.

FDA - U.S. Food and Drug Administration

7-11-2018

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Several store-brand pain or sinus relief tablets recalled because consumers may be unable to access important safety information

Vita Health Products is voluntarily recalling several store-brand (Care, Exact, Life, and Pharmasave) over-the-counter drugs used for pain or sinus relief because of a labelling issue. Consumers may be unable to peel open the wrap-around label on the bottle to access the warning statements, or the label may not peel off completely, which may make it difficult to read some of the important safety information.

Health Canada

6-11-2018

FDA Approves Experior for Reduction of Ammonia Gas Released from Beef Cattle Waste

FDA Approves Experior for Reduction of Ammonia Gas Released from Beef Cattle Waste

FDA announced today the approval of Experior (lubabegron Type A medicated article), a beta-adrenergic agonist/antagonist drug that, when fed to beef cattle under specific conditions, results in less ammonia gas released as a by-product of their waste.

FDA - U.S. Food and Drug Administration

5-11-2018

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

October 31, 2018: Fullerton Man Arrested on Federal Charges Alleging Illegal Importation and Sale of Male Sexual Enhancement Drugs

FDA - U.S. Food and Drug Administration

29-10-2018

Aurobindo Pharma Limited Issues Voluntary Recall of Irbesartan Drug Substance due to the Detection of Trace Amounts of NDEA (NNitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Aurobindo Pharma Limited Issues Voluntary Recall of Irbesartan Drug Substance due to the Detection of Trace Amounts of NDEA (NNitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)

Aurobindo Pharma Limited is voluntarily recalling 22 Batches of the drug substance Irbesartan due to the presence of an impurity, N-nitrosodiethylamine (NDEA). The impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC).

FDA - U.S. Food and Drug Administration

25-10-2018

Nutrition Facts Label Reboot: A Tale of Two Labels

Nutrition Facts Label Reboot: A Tale of Two Labels

The Nutrition Facts Label (NFL) on packages consumers look at when they’re buying groceries or preparing a meal has undergone a makeover. The U.S. Food and Drug Administration (FDA) has changed it to reflect updated scientific findings and help consumers make better-informed choices about the foods their families eat. Until the deadlines, consumers may see two different versions on the products they buy: the original label they’ve been using, as well as the new label. The Consumer Update will emphasize...

FDA - U.S. Food and Drug Administration

24-10-2018

FDA approves new drug to treat influenza

FDA approves new drug to treat influenza

FDA approved Xofluza (baloxavir marboxil) to treat acute uncomplicated flu in patients 12 years old and older who have been symptomatic for less than 48 hours.

FDA - U.S. Food and Drug Administration

23-10-2018

Federal judge enters consent decree against Tennessee over-the-counter drug manufacturer

Federal judge enters consent decree against Tennessee over-the-counter drug manufacturer

A federal court orders a Tennessee-based company to stop selling over-the-counter (OTC) drug products

FDA - U.S. Food and Drug Administration

23-10-2018

FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs; including opioids

FDA launches global operation to crack down on websites selling illegal, potentially dangerous drugs; including opioids

FDA warns website networks as part of global crack down for selling illegal pharmaceuticals

FDA - U.S. Food and Drug Administration

14-12-2018

Review of the Narcotic Drugs Act 1967

Review of the Narcotic Drugs Act 1967

Professor John McMillan AO appointed to review and report on the operation of the Narcotic Drugs Act 1967

Therapeutic Goods Administration - Australia

19-11-2018

By providing more clarity around how these prescription-drug-use-related software products will be regulated, #FDA hopes to promote development of these innovations. We believe these innovative products can help significantly improve patients’ health

By providing more clarity around how these prescription-drug-use-related software products will be regulated, #FDA hopes to promote development of these innovations. We believe these innovative products can help significantly improve patients’ health

By providing more clarity around how these prescription-drug-use-related software products will be regulated, #FDA hopes to promote development of these innovations. We believe these innovative products can help significantly improve patients’ health

FDA - U.S. Food and Drug Administration

19-11-2018

How we regulate this space is important. Consider, for example, a sensor that collects data to track a drug as it moves through the body after being ingested to promote compliance or monitor how a drug is working.

How we regulate this space is important. Consider, for example, a sensor that collects data to track a drug as it moves through the body after being ingested to promote compliance or monitor how a drug is working.

How we regulate this space is important. Consider, for example, a sensor that collects data to track a drug as it moves through the body after being ingested to promote compliance or monitor how a drug is working.

FDA - U.S. Food and Drug Administration

19-11-2018

The #FDA wants to promote the development of #digitaltech that can also help guide the safe and effective use of prescription drugs, to help patients improve their health  https://go.usa.gov/xPAak pic.twitter.com/nRPaMkKini

The #FDA wants to promote the development of #digitaltech that can also help guide the safe and effective use of prescription drugs, to help patients improve their health https://go.usa.gov/xPAak pic.twitter.com/nRPaMkKini

The #FDA wants to promote the development of #digitaltech that can also help guide the safe and effective use of prescription drugs, to help patients improve their health https://go.usa.gov/xPAak  pic.twitter.com/nRPaMkKini

FDA - U.S. Food and Drug Administration

1-11-2018

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here:  https://go.u

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here: https://go.u

The @US_FDA warns patients & health care providers should not change drug treatment based on results from certain genetic tests w/ unapproved claims to predict a patient’s response to specific medications. Read the Safety Communication here: https://go.usa.gov/xPysF  #MedicalDevice

FDA - U.S. Food and Drug Administration

22-10-2018

EU/3/16/1704 (Drug Development and Regulation S.L.)

EU/3/16/1704 (Drug Development and Regulation S.L.)

EU/3/16/1704 (Active substance: Sirolimus) - Transfer of orphan designation - Commission Decision (2018)6988 of Mon, 22 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/045/16/T/01

Europe -DG Health and Food Safety

21-10-2018

Transparency is one way to encourage greater inclusion. Check out our Drug Trials Snapshots - information about who participated in clinical trials supporting a drug’s approval and whether there are any demographic differences in benefits or side effects

Transparency is one way to encourage greater inclusion. Check out our Drug Trials Snapshots - information about who participated in clinical trials supporting a drug’s approval and whether there are any demographic differences in benefits or side effects

Transparency is one way to encourage greater inclusion. Check out our Drug Trials Snapshots - information about who participated in clinical trials supporting a drug’s approval and whether there are any demographic differences in benefits or side effects https://go.usa.gov/xPnVQ . pic.twitter.com/MyoBPe0IGg

FDA - U.S. Food and Drug Administration